We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 15, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Mastercard Inc. (MA - Free Report) , AstraZeneca PLC (AZN - Free Report) and Sandisk Corp. (SNDK - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Mastercard, AstraZeneca and Sandisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard Inc., AstraZeneca PLC and Sandisk Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Mastercard's shares have outperformed the Zacks Financial Transaction Services industry over the past year (+7.2% vs. -5.2%). The company benefits from the secular shift toward electronic payments, supported by a scalable, asset-light model that can convert rising transaction volumes into attractive incremental economics.
Resilient consumer spending and cross-border demand provide revenue visibility, while growing value-added services broaden the earnings base beyond core payment processing. Strategic partnerships, acquisitions and expansion into emerging payment flows further extend its addressable market. Strong cash generation also supports continued reinvestment, acquisitions and shareholder returns.
However, rising rebates and incentives signal greater competitive pricing pressure, while merchant litigation and alternative payment rails could weaken network economics. Its premium valuation also limits upside. As such, we have a Neutral recommendation on the stock.
Shares of AstraZeneca have underperformed the Zacks Medical - Biomedical and Genetics industry over the past year (-7.2% vs. +7.5%). The company's several blockbuster drugs like Farxiga, Brilinta, Symbicort and Soliris have lost patent exclusivity and are facing generic erosion. Recent pipeline setbacks are a concern. Estimates remain mixed ahead of Q3 earnings. The company has a mixed record of earnings surprises in recent quarters.
Nevertheless, AstraZeneca's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra should keep driving revenues. New drugs are also contributing to growth. Two new drugs, Etcamah in breast cancer and Baxfendy in hypertension, are already approved this year.
AstraZeneca's pipeline is also strong, with several pivotal data readouts lined up over the next 18 months. Backed by its new products and pipeline drugs, AstraZeneca expects to generate $80 billion in total revenues by 2030.
Sandisk's shares have outperformed the Zacks Computer- Storage Devices industry over the past year (+927.2% vs. +229.6%). The company is benefiting from AI inference demand that is lifting enterprise SSD needs and increasing datacenter exposure. BiCS8, BiCS9 and BiCS10 support higher density, performance and power efficiency, while long-term customer agreements improve demand visibility and margin durability.
Management also targets substantial free cash flow and continued excess-cash returns to shareholders. Offsetting these positives, supply growth remains deliberately constrained, non-NBM business stays exposed to market pricing, and execution across technology transitions is critical.
HBF adds longer-term optionality but is not yet included in the financial model. These drivers support an Outperform view as structural AI demand, contracted business gains and cash-generation prospects outweigh supply, pricing, customer-mix and execution risks.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk
For Immediate Release
Chicago, IL – October 15, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Mastercard Inc. (MA - Free Report) , AstraZeneca PLC (AZN - Free Report) and Sandisk Corp. (SNDK - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Mastercard, AstraZeneca and Sandisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard Inc., AstraZeneca PLC and Sandisk Corp.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Today's Featured Research Reports
Mastercard's shares have outperformed the Zacks Financial Transaction Services industry over the past year (+7.2% vs. -5.2%). The company benefits from the secular shift toward electronic payments, supported by a scalable, asset-light model that can convert rising transaction volumes into attractive incremental economics.
Resilient consumer spending and cross-border demand provide revenue visibility, while growing value-added services broaden the earnings base beyond core payment processing. Strategic partnerships, acquisitions and expansion into emerging payment flows further extend its addressable market. Strong cash generation also supports continued reinvestment, acquisitions and shareholder returns.
However, rising rebates and incentives signal greater competitive pricing pressure, while merchant litigation and alternative payment rails could weaken network economics. Its premium valuation also limits upside. As such, we have a Neutral recommendation on the stock.
(You can read the full research report on Mastercard here >>>)
Shares of AstraZeneca have underperformed the Zacks Medical - Biomedical and Genetics industry over the past year (-7.2% vs. +7.5%). The company's several blockbuster drugs like Farxiga, Brilinta, Symbicort and Soliris have lost patent exclusivity and are facing generic erosion. Recent pipeline setbacks are a concern. Estimates remain mixed ahead of Q3 earnings. The company has a mixed record of earnings surprises in recent quarters.
Nevertheless, AstraZeneca's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra should keep driving revenues. New drugs are also contributing to growth. Two new drugs, Etcamah in breast cancer and Baxfendy in hypertension, are already approved this year.
AstraZeneca's pipeline is also strong, with several pivotal data readouts lined up over the next 18 months. Backed by its new products and pipeline drugs, AstraZeneca expects to generate $80 billion in total revenues by 2030.
(You can read the full research report on AstraZeneca here >>>)
Sandisk's shares have outperformed the Zacks Computer- Storage Devices industry over the past year (+927.2% vs. +229.6%). The company is benefiting from AI inference demand that is lifting enterprise SSD needs and increasing datacenter exposure. BiCS8, BiCS9 and BiCS10 support higher density, performance and power efficiency, while long-term customer agreements improve demand visibility and margin durability.
Management also targets substantial free cash flow and continued excess-cash returns to shareholders. Offsetting these positives, supply growth remains deliberately constrained, non-NBM business stays exposed to market pricing, and execution across technology transitions is critical.
HBF adds longer-term optionality but is not yet included in the financial model. These drivers support an Outperform view as structural AI demand, contracted business gains and cash-generation prospects outweigh supply, pricing, customer-mix and execution risks.
(You can read the full research report on Sandisk here >>>)
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.